Literature DB >> 26619962

Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.

Kavel Visrodia1, Siddharth Singh2, Rajesh Krishnamoorthi1, David A Ahlquist1, Kenneth K Wang1, Prasad G Iyer1, David A Katzka3.   

Abstract

BACKGROUND & AIMS: A proportion of patients with Barrett's esophagus (BE) are diagnosed with esophageal adenocarcinoma (EAC) within 1 year of an endoscopic examination that produced negative findings. These cases of missed cancers have not been well studied, despite current surveillance strategies for BE. We performed a systematic review and meta-analysis to determine the magnitude of missed EAC in cohorts of patients with BE.
METHODS: We searched MEDLINE, EMBASE, and Web of Science from their inception to May 31, 2015 to identify cohort studies of adults with BE (baseline nondysplastic BE ± BE with low-grade dysplasia) and at least a 3-year follow-up period, providing data on missed and incident EACs (diagnosed within 1 year and diagnosed more than 1 year after the initial endoscopy in which BE was diagnosed, respectively). The main outcome measure was pooled proportion of missed and incident EACs (of all EACs detected after initial endoscopy) among BE cohorts, using a random effects model.
RESULTS: In a meta-analysis of 24 studies reporting on 820 missed and incident EACs, 25.3% were classified as missed (95% confidence interval: 16.4%-36.8%) and 74.7% as incident EACs (95% CI: 63.2%-83.6%), although there was substantial heterogeneity among studies (I2 = 74%). When the analysis was restricted to nondysplastic BE cohorts (15 studies), 23.9% of EACs were classified as missed (95% confidence interval: 15.3%-35.4%; I2 = 0%). In a meta-analysis of 10 studies with follow-up periods of ≥5 years (a total of 239 EACs), 22.0% were classified as missed (95% confidence interval: 8.7%-45.5%), with substantial heterogeneity (I2 = 68%).
CONCLUSIONS: Among adults with nondysplastic BE (or BE with low-grade dysplasia) at their index endoscopy and at least a 3-year follow-up period, 25% of EACs are diagnosed within 1 year after the index endoscopy. Additional resources should be allocated to detect missed EAC.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endoscopy; Esophageal Cancer; Prevalence; Surveillance

Mesh:

Year:  2015        PMID: 26619962      PMCID: PMC4919075          DOI: 10.1053/j.gastro.2015.11.040

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  68 in total

1.  Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus.

Authors:  Hashem B El-Serag; Aanand D Naik; Zhigang Duan; Mohammad Shakhatreh; Ashley Helm; Amita Pathak; Marilyn Hinojosa-Lindsey; Jason Hou; Theresa Nguyen; John Chen; Jennifer R Kramer
Journal:  Gut       Date:  2015-08-26       Impact factor: 23.059

2.  Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.

Authors:  M Sikkema; C W N Looman; E W Steyerberg; M Kerkhof; F Kastelein; H van Dekken; A J van Vuuren; W A Bode; H van der Valk; R J T Ouwendijk; R Giard; W Lesterhuis; R Heinhuis; E C Klinkenberg; G A Meijer; F ter Borg; J W Arends; J J Kolkman; J van Baarlen; R A de Vries; A H Mulder; A J P van Tilburg; G J A Offerhaus; F J W ten Kate; J G Kusters; E J Kuipers; P D Siersema
Journal:  Am J Gastroenterol       Date:  2011-05-17       Impact factor: 10.864

3.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

4.  Adenocarcinoma and Barrett's esophagus. An overrated risk?

Authors:  S J Spechler; A H Robbins; H B Rubins; M E Vincent; T Heeren; W G Doos; T Colton; E M Schimmel
Journal:  Gastroenterology       Date:  1984-10       Impact factor: 22.682

5.  Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group.

Authors:  S J Spechler
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

6.  Adenocarcinoma in Barrett's oesophagus: an overrated risk.

Authors:  A H Van der Veen; J Dees; J D Blankensteijn; M Van Blankenstein
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

7.  Low-grade dysplasia in Barrett's esophagus has a high risk of progression.

Authors:  C H Lim; D Treanor; M F Dixon; A T R Axon
Journal:  Endoscopy       Date:  2007-07       Impact factor: 10.093

8.  Barrett's oesophagus: an audit of surveillance over a 17-year period.

Authors:  Lisa Gladman; Warren Chapman; Tariq H Iqbal; Joan C Gearty; Brian T Cooper
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-03       Impact factor: 2.566

9.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

10.  Effects of autofluorescence imaging on detection and treatment of early neoplasia in patients with Barrett's esophagus.

Authors:  David F Boerwinkel; Jasmin A Holz; Mohammed A Kara; Sybren L Meijer; Michael B Wallace; Louis-Michel Wong Kee Song; Krish Ragunath; Herbert C Wolfsen; Prasad G Iyer; Kenneth K Wang; Bas L Weusten; Maurice C Aalders; Wouter L Curvers; Jacques J G H M Bergman
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-24       Impact factor: 11.382

View more
  51 in total

Review 1.  [Barrett's esophagus].

Authors:  J Labenz
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

2.  Editorial on quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS).

Authors:  Philip Wai Yan Chiu
Journal:  Transl Gastroenterol Hepatol       Date:  2018-02-28

Review 3.  Role of Extracellular Vesicles in the Diagnosis and Pathogenesis of Barrett's Esophagus: A Mini-Review.

Authors:  Qiuyang Zhang; Ajay Bansal
Journal:  Dig Dis Sci       Date:  2020-04-10       Impact factor: 3.199

4.  Enabling precision digestive surgery with fluorescence imaging.

Authors:  Michele Diana
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-21

Review 5.  Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile?

Authors:  Fouad Otaki; Prasad G Iyer
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

Review 6.  Time to Challenge Current Strategies for Detection of Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  David A Katzka; Rebecca C Fitzgerald
Journal:  Dig Dis Sci       Date:  2020-01       Impact factor: 3.199

7.  Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: A multicentric cohort study.

Authors:  Enrique Rodríguez de Santiago; Nerea Hernanz; Héctor Miguel Marcos-Prieto; Miguel Ángel De-Jorge-Turrión; Eva Barreiro-Alonso; Carlos Rodríguez-Escaja; Andrea Jiménez-Jurado; María Sierra-Morales; Isabel Pérez-Valle; Nadja Machado-Volpato; María García-Prada; Laura Núñez-Gómez; Andrés Castaño-García; Ana García García de Paredes; Beatriz Peñas; Enrique Vázquez-Sequeiros; Agustín Albillos
Journal:  United European Gastroenterol J       Date:  2018-10-31       Impact factor: 4.623

8.  Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.

Authors:  M Everson; C Magee; D Alzoubaidi; S Brogden; D Graham; L B Lovat; M Novelli; R Haidry
Journal:  Dig Dis Sci       Date:  2019-04-13       Impact factor: 3.199

9.  Surrogate Markers: Lessons from the Next Gen?

Authors:  Brian J Reid
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-02

Review 10.  Recent Advances in Screening for Barrett's Esophagus.

Authors:  Sarmed S Sami; Prasad G Iyer
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.